CMOs continue to expand their service offerings to include specialized development capabilities, especially contract manufacturers with strengths in formulating poorly soluble compounds. Formulation development, analytical development and characterization, clinical trial manufacturing and commercial manufacturing for drug substance and drug product may be obtained from a single provider with end-to-end services. Knowing whether this is the best approach for your organization is challenging. This report dives into how the decision-making process differs among drug innovators outsourcing development activities from those outsourcing commercial manufacturing when it comes to CMO/CDMO selection criteria, use patterns, preferences and perceived leadership. Readers will gain insight into four different outsourcing scenarios for small molecule drugs enabling them to make more educated purchases of CMO services based on their unique needs. CMOs will gain a better understanding of customers’ requirements and how they change as a compound moves through the development to commercialization process.
Learn more by downloading the free preview file, or by purchasing the full report below.